{
    "id": 60901,
    "name": "Waldenstroem's macroglobulinemia",
    "source": "DOID",
    "definition": "A lymphoplasmacytic lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein. [url:http\\://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=10313, url:https\\://www.ncbi.nlm.nih.gov/pubmed/10632755]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0060901",
    "evidence": [
        {
            "id": 12255,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Imbruvica (ibrutinib) treatment resulted in decreased major response rate in Waldenstroem's macroglobulinemia patients harboring WHIM-like CXCR4 mutations compared to patients with wild-type CXCR4 (30% vs 77%, p=0.018) (Blood 2013, 122 (21): 251).",
            "molecularProfile": {
                "id": 28135,
                "profileName": "CXCR4 mutant"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10216,
                    "pubMedId": null,
                    "title": "A Prospective Multicenter Study Of The Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom\u2019s Macroglobulinemia",
                    "url": "http://www.bloodjournal.org/content/122/21/251?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13546,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYD88 L265P is diagnostic and aids distinguishing Waldenstrom macroglobulinemia from IgM-secreting B-cell lymphomas and IgM plasma cell myeloma (NCCN.org).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13547,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibruvica (ibrutinib) treatment resulted in an overall response rate of 90.5% and a major response rate of 73.0% in patients with previously treated Waldenstr\u00f6m's macroglobulinemia, with the best response seen in patients harboring the MYD88 L265P and wild-type CXCR4 genotype (100%, 91.2%, 35 patients), followed by MYD88 L265P and mutant CXCR4 (85.7%, 61.9%, 21 patients), then wild-type MYD88 and CXCR4 (71.4%, 28.6%, 7 patients) (PMID: 25853747; NCT01614821).",
            "molecularProfile": {
                "id": 9814,
                "profileName": "CXCR4 wild-type MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2810,
                    "pubMedId": 25853747,
                    "title": "Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25853747"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13548,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibruvica (ibrutinib) treatment resulted in an overall response rate of 90.5% and a major response rate of 73.0% in patients with previously treated Waldenstr\u00f6m's macroglobulinemia, with the best response seen in patients harboring the MYD88 L265P and wild-type CXCR4 genotype (100%, 91.2%, 35 patients), followed by MYD88 L265P and mutant CXCR4 (85.7%, 61.9%, 21 patients), then wild-type MYD88 and CXCR4 (71.4%, 28.6%, 7 patients) (PMID: 25853747; NCT01614821).",
            "molecularProfile": {
                "id": 29152,
                "profileName": "CXCR4 mut MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2810,
                    "pubMedId": 25853747,
                    "title": "Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25853747"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13549,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibruvica (ibrutinib) treatment resulted in an overall response rate of 90.5% and a major response rate of 73.0% in patients with previously treated Waldenstr\u00f6m's macroglobulinemia, with the best response seen in patients harboring the MYD88 L265P and wild-type CXCR4 genotype (100%, 91.2%, 35 patients), followed by MYD88 L265P and mutant CXCR4 (85.7%, 61.9%, 21 patients), then wild-type MYD88 and CXCR4 (71.4%, 28.6%, 7 patients) (PMID: 25853747; NCT01614821).",
            "molecularProfile": {
                "id": 29153,
                "profileName": "CXCR4 wild-type MYD88 wild-type"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2810,
                    "pubMedId": 25853747,
                    "title": "Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25853747"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13897,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Umbralisib (TGR-1202) treatment resulted in stable disease in 2 patients with Waldenstroem's macroglobulinemia (PMID: 29475723; NCT01767766).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2022,
                "therapyName": "Umbralisib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11343,
                    "pubMedId": 29475723,
                    "title": "Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29475723"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18620,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Oprozomib (ONX 0912) treatment resulted in an objective response rate of 71.4% and 47.1% in the 2/7 and 5/14 cohorts of patients with Waldenstroem's macroglobulinemia (n=31) (PMID: 31142508; NCT01416428).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2422,
                "therapyName": "Oprozomib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16360,
                    "pubMedId": 31142508,
                    "title": "A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstr\u00f6m Macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31142508"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02339922",
            "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6730,
                    "therapyName": "Ixazomib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576496",
            "title": "Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6104,
                    "therapyName": "Tinostamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03147885",
            "title": "Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03162536",
            "title": "Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5224,
                    "therapyName": "ARQ 531",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03364231",
            "title": "Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2022,
                    "therapyName": "Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03498612",
            "title": "Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03557619",
            "title": "A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7978,
                    "therapyName": "Ethinylestradiol + Levonorgestrel + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03711578",
            "title": "Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2020,
                    "therapyName": "RP6530",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03740529",
            "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9507,
                    "therapyName": "Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine",
                    "synonyms": "LOXO-305 + R-CHOP"
                },
                {
                    "id": 9506,
                    "therapyName": "LOXO-305 + Rituximab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 9505,
                    "therapyName": "LOXO-305 + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 9504,
                    "therapyName": "LOXO-305",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03779113",
            "title": "An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5279,
                    "therapyName": "HMPL-523",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03786926",
            "title": "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3669,
                    "therapyName": "HMPL-689",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03920631",
            "title": "Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04052854",
            "title": "A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 2544,
                    "therapyName": "Zanubrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04273139",
            "title": "Ibrutinib + Venetoclax in Untreated WM",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 3392,
                    "therapyName": "Ibrutinib + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04274738",
            "title": "A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9405,
                    "therapyName": "Ibrutinib + X4P-001",
                    "synonyms": null
                }
            ]
        }
    ]
}